[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352623-105":59,"doc-detail-352623-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","harnessing-pdx-and-pdx-20-the-next-generation-paradigm-for-precision-oncology-and-translational-breakthroughs","Harnessing PDX and PDX 2.0 - the next-generation paradigm for precision oncology and translational breakthroughs","","Cancer research has benefited from patient-derived xenograft (PDX) models, yet conventional PDX limitations increasingly hinder clinical translation. In 2025, NIH shifted funding away from animal-model-only approaches toward justified integration of novel alternative methods (NAMs). Still, NAMs cannot fully replace PDXs because of ongoing immaturity and uncertainty, requiring sustained methodological development. This review proposes PDX 2.0, integrating NAMs and complementary technologies to improve precision, efficiency, and clinical actionability.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/harnessing-pdx-and-pdx-20-the-next-generation-paradigm-for-precision-oncology-and-translational-breakthroughs/352623/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/harnessing-pdx-and-pdx-20-the-next-generation-paradigm-for-precision-oncology-and-translational-breakthroughs/352623.png","ImageObject",300,407,{"name":92,"@type":93},"Jacob","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What limitations of conventional PDX models affect clinical translation?","Question",{"text":113,"@type":114},"Conventional PDX models show constraints such as time lag, microenvironmental shifts, subclone selection, metastasis-related discrepancies, immunodeficiency, and high labor intensity, which limit translational utility.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Why can’t NAMs fully replace PDX models yet?",{"text":118,"@type":114},"NAMs remain immature and unstable for addressing complex biological questions, so uncertainties prevent complete replacement at present.",{"name":120,"@type":111,"acceptedAnswer":121},"What is PDX 2.0 and how does it differ from traditional PDX models?",{"text":122,"@type":114},"PDX 2.0 is a conceptual framework that advances conventional PDX by systematically integrating NAMs and complementary technologies, aiming to enable more efficient and precise cancer research for clinically actionable precision oncology.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352623,1790551836,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Jian et al. Molecular Cancer (2026) 25:82 [https://doi.org/10.1186/s12943-026-02594-w](https://doi.org/10.1186/s12943-026-02594-w)  \nMolecular Cancer  \nREVIEW Open Access  \nHarnessing PDX and PDX 2.0: the next- generation paradigm for precision oncology and translational breakthroughs  \nChengli Jian1†, Hao Fu1†, Wantao Wu2†, Nan Zhang3, Zaoqu Liu4, Zhiwei Xia5,6*, Peng Luo1,7*, Hao Zhang1,9* and Quan Cheng8,9,10,11,12*  \nAbstract  \nCancer research has achieved remarkable breakthroughs over the past decades with the aid of patient-derived xenograft (PDX) models. However, the limitations of conventional PDX models in hindering clinical translation have become increasingly apparent. In 2025, the National Institutes of Health (NIH) announced a funding shift away from exclusive reliance on animal models without justified integration of novel alternative methods (NAMs), humanrelevant modeling approaches. Nevertheless, PDX models cannot be fully replaced currently due to the lingering immaturity and uncertainties of NAMs technologies, indicating that a complete non-animal research paradigm will require sustained methodological development. Therefore, developing an innovative, optimized PDX model to navigate this transitional phase remains the holy grail of preclinical cancer research. Herein, we propose PDX 2. 0, a novel conceptual framework that advances conventional PDX models via the systematic integration of NAMsand complementary technologies, thereby enabling more efficient and precise cancer research. This review first delineates the core determinants, major applications, and critical limitations of traditional PDX models, then defines the conceptual architecture and distinctive characteristics of PDX 2.0. We further highlight emerging applications of this framework in high-throughput drug screening, biomarker discovery, and adaptive therapeutic evaluation, positioning PDX 2.0 as a critical evolution of PDX-based research to better support clinically actionable precision oncology.  \nKeywords PDX, PDX 2 . 0, Cancer Research, Precision Medicine, NAMs  \n†Chengli Jian, Hao Fu and Wantao Wu contributed equally to this work.  \n*Correspondence: Zhiwei Xia  \nxiazhiwei201 [1@gmail.com](1@gmail.com)  \nPeng Luo [luopeng@smu.edu.cn](luopeng@smu.edu.cn)[ ](luopeng@smu.edu.cn)Hao Zhang [zhsw@hospital.cqmu.edu.cn](zhsw@hospital.cqmu.edu.cn)[ ](zhsw@hospital.cqmu.edu.cn)Quan Cheng [chengquan@csu.edu.cn](chengquan@csu.edu.cn)  \nFull list of author information is available at the end of the article  \nIntroduction  \nThe patient-derived xenograft (PDX) models are preclinical research platforms using immunodeficient mice to implant cancerous tissues and cells from tumor patients, thereby obtaining a series of characteristics similar to the primary tumor. It has elucidated partial mechanisms of tumors and developed drugs based on the differences in the molecular characteristics of malignant tumors to promote the development of personalized medicine (precision medicine) [1, 2]. The most significant feature of the PDX model is that it can retain the heterogeneity of the primary tumor to some extent, including the molecular  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutor","cbCaikMGxmyOSiga","https://ap.wps.com/l/cbCaikMGxmyOSiga","pdf",8027871,37,"English","# Abstract\n## Introduction\n## PDX limitations and translational constraints\n## Emergence of NAMs and integration strategy","[{\"question\":\"What limitations of conventional PDX models affect clinical translation?\",\"answer\":\"Conventional PDX models show constraints such as time lag, microenvironmental shifts, subclone selection, metastasis-related discrepancies, immunodeficiency, and high labor intensity, which limit translational utility.\"},{\"question\":\"Why can’t NAMs fully replace PDX models yet?\",\"answer\":\"NAMs remain immature and unstable for addressing complex biological questions, so uncertainties prevent complete replacement at present.\"},{\"question\":\"What is PDX 2.0 and how does it differ from traditional PDX models?\",\"answer\":\"PDX 2.0 is a conceptual framework that advances conventional PDX by systematically integrating NAMs and complementary technologies, aiming to enable more efficient and precise cancer research for clinically actionable precision oncology.\"}]","Harnessing PDX and PDX 2.0 - the next-generation paradigm for precision oncology and translational breakthroughs | PDF",1790100520,93,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d74fe81b7d8f5d18d85f9a9b0dc14f6f.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26e6282e574f8dd58aa107581853ab23.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a4d0cac287b0ecadf8924f297aad44e5.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0ae23bcb20d5ae297bc748b003980a91.webp",980,1306]